Development of matrix metalloproteinase inhibitors in cancer therapy.

By M. Hidalgo, S. Eckhardt. Journal of the National Cancer Institute, 2001

756 citations recorded by the source corpus.

Subfields: Cancer Research, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/0502a0a7079787fad450bdebbd591a46e016da33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Hematology

In Oncology

Citations in the corpus

The ADAMs family of metalloproteases: multidomain proteins with multiple functions. (2003, background): “Several hydroxamate-based inhibitors have been tested in preclinical and clinical settings (Hidalgo and Eckhardt 2001).”
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. (2009, background): “Musculoskeletal toxicity has also been reported in clinical trials with prinomastat and BMS-275291.”
Matrix metalloproteinases: role in arthritis. (2006, background): “Chemical groups that bind zinc include the carboxylates, aminocarboxylates, sulfhydryls, phosphoric acid derivatives, and hydroxymates, all of which have been tested for their ability to inhibit MMP activity (94).”
Axis of evil: molecular mechanisms of cancer metastasis (2003, background): “However, recent data indicate that MMP inhibitors could be more successful when used in early-stage cancer or in combination with traditional treatment modalities (Zucker et al., 2000; Hidalgo and Eckhardt, 2001).”
New functions for the matrix metalloproteinases in cancer progression (2002, methodology): “Tetracycline analogues without antibiotic activity have been developed for the treatment of cancer (by removal of a dimethylamino group”
Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis (2003, background): “This may account for the limited efficacy of MMP inhibitors in clinical trial”
Extracellular matrix remodelling: the role of matrix metalloproteinases (2003, background): “Examples include tetracycline derivatives that block both the synthesis and activity of MMPs [129].”
Putting tumours in context (2001, result): “Although the results with patients suffering from advanced stages of cancer have shown no clinical efficacy, recent data indicate that MMP inhibitors could be more successful when used in early-stage cancer or in conjunction with traditional treatment method”
Stromal biology and therapy in pancreatic cancer (2010, background): “For instance, matrix metalloproteinases (MMPs) are a large family of zinc-containing proteolytic enzymes involved in the degradation, dynamic remodelling and turnover of ECM proteins in physiological and pathological conditions.27 In particular, MMP-2 and MMP-9 are commonly overexpressed in pancreat”
Strategies for MMP inhibition in cancer: innovations for the post-trial era (2002, background): “, most clinical studies that involve synthetic MMPIs have not, unfortunately, shown significant efficacy in patients with advanced cance”